Welcome to the MedLibrary.org Wikipedia Supplement on Sulfonylurea -- Please Click to Return to Front Page

Sulfonylurea (UK: Sulphonylurea) derivatives are a class of antidiabetic drugs that are used in the management of diabetes mellitus type 2 ("adult-onset"). They act by increasing insulin release from the beta cells in the pancreas.

Contents 1 Drugs in this class 1.1 First generation 1.2 Second generation 1.3 Third generation 2 Chemistry 3 Pharmacology 3.1 Mechanism of action 3.2 Pharmacokinetics 4 Uses 5 Side-effects and cautions 6 History 7 See also 8 References

Drugs in this class

First generation

• Acetohexamide
• Chlorpropamide
• Tolbutamide
• Tolazamide

Second generation

• Glipizide
• Gliclazide
• Glibenclamide (glyburide)
• Gliquidone
• Glyclopyramide

Third generation

• Glimepiride

Chemistry

All sulfonylureas contain a central sulfonylurea structure with p-substitution on the phenyl ring and various groups terminating the urea N' end group.

Pharmacology

Mechanism of action

Sulfonylureas bind to an ATP-dependent K⁺ (K_ATP) channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca²⁺ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.

There is some evidence that sulfonylureas also sensitize β-cells to glucose, that they limit glucose production in the liver, that they decrease lipolysis (breakdown and release of fatty acids by adipose tissue) and decrease clearance of insulin by the liver.

The K_ATP channel in turn is a complex of the inward-rectifier potassium ion channel K_ir6.2 and sulfonylurea receptor SUR1 which associate with a stoichiometry of K_ir6.2₄/SUR1₄.

Pharmacokinetics

Various sulfonylureas have different pharmacokinetics. The choice depends on the propensity of the patient to develop hypoglycemia - long-acting sulfonylureas with active metabolites can induce hypoglycemia. They can, however, help achieve glycemic control when tolerated by the patient. The shorter-acting agents may not control blood sugar levels adequately.

Due to varying half-life, some drugs have to be taken twice (e.g. tolbutamide) or three times a day rather than once (e.g. glimepiride). The short-acting agents may have to be taken about 30 minutes before the meal, to ascertain maximum efficacy when the food leads to increased blood glucose levels.

Some sulfonylureas are metabolised by liver metabolic enzymes (cytochrome P450) and inducers of this enzyme system (such as the antibiotic rifampicin) can therefore increase the clearance of sulfonylureas. In addition, because some sulfonylureas are bound to plasma proteins, use of drugs that also bind to plasma proteins can release the sulfonylureas from their binding places, leading to increased clearance.

Uses

Sulfonylureas are used almost exclusively in diabetes mellitus type 2. Sulfonylureas are ineffective where there is absolute deficiency of insulin production such as in type 1 diabetes or post-pancreatectomy.

Although for many years sulfonylureas were the first drugs to be used in new cases of diabetes, in the 1990s it was discovered that obese patients might benefit more from metformin.

In about 10% of patients, sulfonylureas alone are ineffective in controlling blood glucose levels. Addition of metformin or a thiazolidinedione may be necessary, or (ultimately) insulin. Triple therapy of sulfonylureas, a biguanide (metformin) and a thiazolidinedione is generally discouraged, but some doctors prefer this combination over resorting to insulin.

More recently, a pharmaceutical startup, Remedy Pharmaceuticals, Inc. has begun developing intravenous glyburide^[1] as a treatment for acute stroke, traumatic brain injury and spinal cord injury based on the identification of a non-selective ATP-gated cation channel which is upregulated in neurovascular tissue during these conditions and closed by sulfonylurea agents.^[2][3]

Some diabetes experts feel that sulfonylureas accelerate the loss of beta cells from the pancreas, and should be avoided.^{citation needed}

Side-effects and cautions

Sulfonylureas, as opposed to metformin, the thiazolidinediones, exenatide, symlin and other newer treatment agents induce hypoglycemia as a result of intermittent excesses in insulin production and release. Thus use of these agents, as with extra insulin from ouside the body, typically prevents achieving good glucose control; people usually keep their blood glucose elevated above optimal in order to reduce the frequency and severity of hypoglycemia. Hypoglycemia is treated with increasing sugar in take by mouth or injection, or (in the case of hypoglycemic coma) with parenteral (injected into the skin or muscle) glucagon and intravenous dextrose.

Like insulin, sulfonylureas can induce weight gain, mainly as a result of edema and reduction of the osmotic diuresis caused by hyperglycemia. Other side-effects are: abdominal upset, headache and hypersensitivity reactions.

Sulfonylureas are potentially teratogenic and cannot be used in pregnancy or in patients who may become pregnant. Impairment of liver or kidney function increase the risk of hypoglycemia, and are contraindications. As other anti-diabetic drugs cannot be used either under these circumstances, insulin therapy is typically recommended during pregnancy and in hepatic and renal failure, although some of the newer agents offer potentially better options.

Second-generation sulfonylureas have increased potency by weight, compared to first-generation sulfonylureas. They have decreased side effects but are more expensive.

History

Sulfonylureas were discovered by the chemist Marcel Janbon and co-workers,^[4] who were studying sulfonamide antibiotics and discovered that the compound sulfonylurea induced hypoglycemia in animals.^[5]

See also

• diabetes mellitus
• metformin
• thiazolidinediones

References

v • d • e Oral antidiabetic drugs and Insulin analogs (A10) Insulin sensitizers Biguanides Metformin, Buformin‡, Phenformin‡ TZDs (PPAR) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ Secretagogues Sulfonylureas 1st generation: Carbutamide, Chlorpropamide, Gliclazide, Tolbutamide, Tolazamide 2nd generation: Glipizide, Glibenclamide (Glyburide), Gliquidone, Glyclopyramide 3rd generation: Glimepiride Meglitinides Nateglinide, Repaglinide, Mitiglinide Glucagon-like peptide-1 analog Exenatide, Liraglutide†, Albiglutide†, Taspoglutide† DPP-4 inhibitors Alogliptin†, Linagliptin†, Saxagliptin†, Sitagliptin, Vildagliptin Alpha-glucosidase inhibitors Acarbose, Miglitol, Voglibose Amylin analog Pramlintide Experimental Dual PPAR agonists Aleglitazar†, Muraglitazar§, Tesaglitazar§ SGLT2 inhibitor Dapagliflozin†, Remogliflozin†, Sergliflozin† Insulin analogs fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera) †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.

Wikipedia content modification information:

• This page was last modified on 12 August 2008, at 10:36.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Sulfonylurea".

The URL for this specific entry is:

• http://medlibrary.org/medwiki/Sulfonylurea

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.